New findings shed light on selective therapeutics for IDH1-mutated glioma

April 13, 2020

Findings of a new study led by Prof. XU Guowang from the Dalian Institute of Chemical Physics (DICP) of the Chinese Academy of Sciences and Prof. YANG Chunzhang from the National Cancer Institute shed light on the selective therapeutics for IDH1-mutated glioma by targeting glutathione synthesis pathway.

The study was published in Proceedings of the National Academy of Sciences on Apr. 14. Glioma is the most common type of primary brain tumors. Isocitrate dehydrogenase I (IDH1) mutation is a cancer-associated mutation highly prevalent in patients with glioma.

Although the oncogenic role of IDH1 mutation has been shown in several human solid tumors, selective therapeutics for IDH1-mutated malignancies remain unavailable.

The researchers demonstrated that glutathione de novo synthesis plays an essential role in IDH1-mutated cancer cells. Glutathione synthesis was controlled by a transcription factor NF-E2-related factor 2 (Nrf2), which governs the gene expressions for antioxidative pathway.

"Our in vitro findings suggest that the disruption of Nrf2-driven glutathione synthesis pathway establishes synergistic lethality with a neomorphic IDH1 mutation, " said Prof. XU.

Triptolide, a diterpenoid epoxide from Tripterygium wilfordii, served as a potent Nrf2 inhibitor. "Triptolide exhibited selective cytotoxicity to patient-derived IDH1-mutated glioma cells in vitro and in vivo. Furthermore, we studied the anticancer mechanism of triptolide." YANG said.

Mechanistically, triptolide compromised the expression of GCLC, GCLM, and SLC7A11, which disrupted glutathione metabolism and established synthetic lethality with reactive oxygen species (ROS) derived from IDH1 mutant neomorphic activity.

The study highlights triptolide as a valuable therapeutic approach for IDH1-mutated malignancies by targeting the Nrf2-driven glutathione synthesis pathway.
-end-


Chinese Academy of Sciences Headquarters

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.